期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血清胱抑素C对两种不同透析方式效果的评价 被引量：3

下载PDF
导出
摘要 低分子质量蛋白质（low molecular weight proteins,LMWPs）是血液透析（hemodialysis,HD）后引起并发症的重要因素,寻找一个理想的指标来评价血液透析对LMWPs清除的效率十分必要。血清胱抑素C（cystatin C,Cys C）属非糖基化单体蛋白质,其血液浓度取决于肾小球滤过率（glomerular filtrationrate,GFR）,
作者 王永志 高术琦 张桂宏 章毅
机构地区 北京市第六医院检验科
出处 《北京医学》 CAS 2009年第5期305-306,共2页 Beijing Medical Journal
关键词 血清胱抑素C 血液透析 方式效果 肾小球滤过率 低分子质量 非糖基化 血液浓度 蛋白质
分类号 R459.5 [医药卫生—治疗学]
  • 相关文献

参考文献8

  • 1Bicik Z,Bahcebasi T,Kulaksizoglu S,et al.The efficacy of cystatin C assay in the prediction of glomemlar filtration rate.Is it a more reliable marker for renal failure? Clin Chem Lab Med,2005,43:855-861.
  • 2Canaud B,Morena M,Cristol JP,et al.Bela micmglobulin,a uremic toxin with a double meaning.Kidney Int,2006,69:1297-1299.
  • 3Leypoldt JK,Cheung AK,Deeter RB.Rebound kinetics of bela2 microglobulin after hemodialysis.Kidney Int,1999,56:1571-1577.
  • 4Abrabanlson M,Olafason I,palsdottir A,et al.Structure and expression of the human cystatin C gene.Biochem J,1990,268:287-294.
  • 5Grubb AO.Cystatin Cproperties and use as a diagnostic marker.Adv Clin Chem,2000,35:63-99.
  • 6Finney H,Williams AH,Price CP.Serum eystatin C in patients with myeloma.Clin Chim Acta,2001,309:1-6.
  • 7叶智明,史伟,梁馨苓,刘双信,王文健,彭炎强.不同透析方式及透析膜对清除血清胱抑素C的效果比较[J].新医学,2006,37(6):362-363. 被引量：14
  • 8Varela Lema L.Ruano Ravina A.Effectiveness and safety of different hemodialysis modalities:a review.J Nephrol,2007,20:525-542.

二级参考文献10

  • 1钱家麒.关注血液透析中若干问题,进一步提高血液透析治疗水平[J].中华肾脏病杂志,2005,21(2):63-64. 被引量：30
  • 2BICIK Z,BAHCEBASI T,KULAKSIZOGLU S,et al.The efficacy of cystatin C assay in the prediction of glomerular filtration rate.is it a more reliable marker for renal failure[J] ? Clin Chem Lab Med,2005,43 (8):855-861.
  • 3KOENIG W,TWARDELLA D,BRENNER H,et al.Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events:more than simply a marker of glomerular filtration rate[J].Clin Chem,2005,51 (2):321-327.
  • 4LOCSEY L,SZEGEDI J,DAN A,et al.Homocysteine and cystatin C level changes in haemodialysed patients and connection with cerebro and cardiovascular complications[J].Acta Physiol Hung,2001,88 (3):293-299.
  • 5BOSTOM AG,KRONENBERG F,RITZ E,et al.Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels[J].J Am Soc Nephrol,2002,13 (8):2140-2144.
  • 6JERNBERG T,LINDAHL B,JAMES S,et al.Cystatin C:a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome[J].Circulation,2004,110(16):2342-2348.
  • 7FELLAH H,FEKI M,HSAIRI M,et al.Hyperhomocysteinemia and end-stage renal disease:determinants and association with cardiovascular disease in Tunisian patients[J].Clin Chem Lab Med,2003,41 (9):675-680.
  • 8刘航,陈香美.胱蛋白酶抑制剂C与肾脏[J].中国实验诊断学,2001,5(4):151-153. 被引量：24
  • 9涂学亮,王登平,薛燕萍,高丰厚.半胱氨酸蛋白酶抑制剂C测定的临床应用研究进展(文献综述)[J].放射免疫学杂志,2003,16(3):178-180. 被引量：4
  • 10谭若芸,王笑云.尿毒症毒素与心血管病变[J].中国血液净化,2004,3(2):104-106. 被引量：15

共引文献13

同被引文献31

  • 1单亦升,田信奎,汪涛.KT/Vurea和Ccr是否适合作为腹膜透析充分性指标的理论探讨[J].生物医学工程学杂志,2007,24(1):140-144. 被引量：8
  • 2Vanholder R, De Smet R, Glorieux G, et al. (European Uremic Toxin Work Group, EUTox): Review on uremic toxins: classification, concen- tration, and inter-individual variability[J]. Kidney Int,2003,63(8) : 1934 - 1943.
  • 3Newman DJ. Cystatin C[J]. Ann Clin Bioehem,2002,39(2):89- 104.
  • 4M. Alan Brookhart, Sebastian Schneeweiss, Jerry Avorn, et al. Compara- tive Mortality Risk of Anemia Management Practices in Incident HemedMy- sis Patients[J]. JAMA, 2010,303(9) : 857 - 864.
  • 5Rottmn Fiedler, Peter M Jehle, Bemd Ostenl, et al. Clinical nutrition scores are superior for the prognosis of haemodialysis patients compared to lab markers and bioelectrieal impedance [ J ]. Nephrol Dial Transplant, 2007,24(12) :3812 - 3817.
  • 6Djousse L, Kurlh T, Gaziano JM. Cystatin C and risk of heart failure in the Physicians' Health Study (PHS) LJ]. Am Heart J,2008,155(3) :82- 86.
  • 7Lameire N, Van BW, Vanholder R. The changing epidemiology of acute renal failure[J]. Nat Clin Pract Nephrol, 2006, 2:364-377.
  • 8Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically illpatients:a multinational, multicenterstudy [J]. JA- MA, 2005, 294:813-818.
  • 9Mattes WB, Walker EC. Translational toxicology and thework of the predictive safety testing consortiu [J]. Clin Pharmacol Ther, 2009, 85:327-330.
  • 10Rouse RL, Zhang J, Stewart SR. Comparative profile of commer- cially available urinary biomarkers in preclinical drug-induced kidney injury and recovery in rats [J]. Kidney Int, 2011, 79: 1186-1197.

引证文献3

二级引证文献7

北京医学
2009年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部